oxybutynin has been researched along with Warts in 3 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Warts: Benign epidermal proliferations or tumors; some are viral in origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse events and adverse drug reactions, the concentrations of FIT039, and surface area of cutaneous warts were evaluated." | 6.90 | Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts. ( Amino, Y; Asada, R; Hagiwara, M; Kabashima, K; Nomura, T; Sawada, T; Sumi, E; Tada, H; Uozumi, R; Yonezawa, A, 2019) |
| " Adverse events and adverse drug reactions, the concentrations of FIT039, and surface area of cutaneous warts were evaluated." | 2.90 | Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts. ( Amino, Y; Asada, R; Hagiwara, M; Kabashima, K; Nomura, T; Sawada, T; Sumi, E; Tada, H; Uozumi, R; Yonezawa, A, 2019) |
| "Warts are a common skin disease caused by infection of the human papilloma virus." | 2.87 | Efficacy of a bleomycin microneedle patch for the treatment of warts. ( Baek, JO; Jeong, HR; Kim, HJ; Kim, JS; Lee, SK; Park, JH; Roh, JY; Ryu, HR; Seon-Woo, HS, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, HR | 1 |
| Jeong, HR | 1 |
| Seon-Woo, HS | 1 |
| Kim, JS | 1 |
| Lee, SK | 1 |
| Kim, HJ | 1 |
| Baek, JO | 1 |
| Park, JH | 1 |
| Roh, JY | 1 |
| Sumi, E | 1 |
| Nomura, T | 1 |
| Asada, R | 1 |
| Uozumi, R | 1 |
| Tada, H | 1 |
| Amino, Y | 1 |
| Sawada, T | 1 |
| Yonezawa, A | 1 |
| Hagiwara, M | 1 |
| Kabashima, K | 1 |
| Antaya, RJ | 1 |
| del Carmen, M | 1 |
| Alonso, F | 1 |
| Sukumar, N | 1 |
| Yong, F | 1 |
| Dvoretzky, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of Occlusive Heat Patch Vs. No Treatment in the Treatment of Verruca[NCT01746056] | 73 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for oxybutynin and Warts
| Article | Year |
|---|---|
Efficacy of a bleomycin microneedle patch for the treatment of warts.
Topics: Adolescent; Adult; Antiviral Agents; Bleomycin; Child; Child, Preschool; Cryotherapy; Female; Humans | 2018 |
Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts.
Topics: Adhesives; Administration, Cutaneous; Adult; Aged; Cryotherapy; Cyclin-Dependent Kinase 9; Female; H | 2019 |
An Open Label Study of an Occlusive Heat Patch in the Treatment of Warts
Topics: Administration, Cutaneous; Child; Female; Fingers; Hand; Hot Temperature; Humans; Hyperthermia, Indu | 2019 |